Treatment of anaerobic infections with lincomycin and clindamycin
JG Bartlett, VL Sutter, SM Finegold - New England Journal of …, 1972 - Mass Medical Soc
JG Bartlett, VL Sutter, SM Finegold
New England Journal of Medicine, 1972•Mass Medical SocThe efficacy of lincomycin and clindamycin against anaerobic bacteria was evaluated by in
vitro sensitivity studies and clinical observations. Ninety-six per cent of 219 stock strains of
various anaerobes were sensitive to 3.1 μg per milliliter of clindamycin, including 96 per cent
of 123 strains of Bacteroides fragilis. All but two strains (both Fusobacterium varium) were
inhibited by 6.2 μg per milliliter, a clinically achievable level. Most species tested were also
sensitive, although less so, to lincomycin. Resistant organisms included most B. fragilis and …
vitro sensitivity studies and clinical observations. Ninety-six per cent of 219 stock strains of
various anaerobes were sensitive to 3.1 μg per milliliter of clindamycin, including 96 per cent
of 123 strains of Bacteroides fragilis. All but two strains (both Fusobacterium varium) were
inhibited by 6.2 μg per milliliter, a clinically achievable level. Most species tested were also
sensitive, although less so, to lincomycin. Resistant organisms included most B. fragilis and …
Abstract
The efficacy of lincomycin and clindamycin against anaerobic bacteria was evaluated by in vitro sensitivity studies and clinical observations. Ninety-six per cent of 219 stock strains of various anaerobes were sensitive to 3.1 μg per milliliter of clindamycin, including 96 per cent of 123 strains of Bacteroides fragilis. All but two strains (both Fusobacterium varium) were inhibited by 6.2 μg per milliliter, a clinically achievable level. Most species tested were also sensitive, although less so, to lincomycin. Resistant organisms included most B. fragilis and many Clostridium perfringens strains.
The patients treated had infections due to a variety of anaerobes, including B. fragilis. Response was favorable in 10 of 11 patients who were treated with lincomycin and in each of 14 patients treated with clindamycin. The data suggest that these agents, particularly clindamycin, are useful in the therapy of anaerobic infections.
The New England Journal Of Medicine